Seelos Therapeutics Inc (SEEL)

[califax]

Apricus Bio's VP of Investor Relations, Edward Cox, Interviewed by Steve Crowley's American Scene

http://www.finanznachrichten.de/nachrichten-2010-11/18497861-apricus-bio-s-vp-of-investor-relations-edward-cox-interviewed-by-steve-crowley-s-american-scene-004.htm

Apricus Biosciences, Inc., ("Apricus Bio") (Nasdaq: APRI) today announced today that Edward Cox, Vice President of Investor Relations, was recently interviewed by "Steve Crowley's American Scene," a radio broadcast on the Money Channel produced by IRNUSA News. To access the interview, go to: http://www.youtube.com/user/Apricusbio#p/u/0/cbybcr3IAmg

During the interview, Mr. Cox highlighted Apricus Bio's latest achievements, including the recent securities offering which raised over $9.3 million in gross proceeds, intended for product and technology development, and general corporate purposes. According to Mr. Cox, the offering put Apricus Bio in a strong operating position to execute on its growth strategy, including the out-licensing of its NexACT® technology and partnering of Apricus Bio's 13 product candidates, which are in various stages of pre-clinical and clinical development.

About Apricus Biosciences

Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to successfully execute on its business plans. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K and subsequent quarterly reports filed on Form 10-Q. Copies of these reports are available from the SEC's website or without charge from the Company.

Contacts:

Apricus Biosciences
Edward Cox, 858-848-4249
V.P. Investor Relations
[e-mail]
or
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
[e-mail]


© 2010 Business Wire